NMN and Heart Health: What the Cardiovascular Evidence Shows

NMN and cardiovascular health are connected through a precise biochemical pathway: NAD+ is required for the enzymatic function of sirtuins and PARP enzymes in vascular cells, and as NAD+ levels fall with age, vascular tissue is among the first to show functional decline. Cardiovascular disease remains the leading cause of death globally, and the relationship between cellular aging—driven partly by NAD+ depletion—and vascular dysfunction is increasingly well-characterized in both animal models and emerging human data.

The Evidence Base

Cardiovascular outcomes are difficult to study in short-term supplement trials, which is why the current NMN evidence base relies primarily on three types of research: mechanistic studies in cell culture, interventional trials in aged animal models, and a growing number of human trials measuring surrogate vascular endpoints rather than clinical events.

The table below outlines NMN's proposed cardiovascular mechanisms and available human evidence by dose:

Dose / Study	Cardiovascular Endpoint	Mechanism	Evidence Level
250 mg/day	NAD⁺ elevation in blood; indirect vascular support	Sirtuin activation → endothelial function	Low (indirect markers)
500 mg/day (Imai 2021 pilot)	Improved gait speed & muscle endurance	Mitochondrial energy in cardiac & skeletal muscle	Moderate (pilot RCT)
Mouse models (high-dose)	Reduced arterial stiffness, improved blood flow in aged mice	eNOS activation, SIRT1-mediated vascular repair	Preclinical only
General: NAD⁺ decline with age	Associated with hypertension, reduced VO₂max	Mitochondrial biogenesis, NAMPT pathway	Observational / mechanistic

In animal studies, the evidence is consistent and strong. Mills et al. (2016) demonstrated that oral NMN administration in aged mice restored vascular NAD+ levels, improved endothelial function, and reduced arterial stiffness—effects comparable to those seen in younger animals. A follow-on study by de Picciotto et al. (2016) in Cell Metabolism specifically measured carotid artery stiffness and endothelium-dependent dilation, finding both were significantly improved in aged mice receiving NMN compared with controls. The mechanisms observed in these studies translate reasonably well to human vascular biology, though direct extrapolation requires caution given the metabolic differences between rodents and humans.

For human data, the picture is more limited but promising. Irie et al. (2020) in the Endocrine Journal confirmed oral NMN is rapidly converted to NAD+ in circulating blood in healthy Japanese men, with dose-dependent increases in NAD+ metabolites. The landmark Yoshino et al. (2021) Science trial—the most rigorous NMN human RCT published to date—found improved skeletal muscle insulin sensitivity at 250 mg/day over 10 weeks in postmenopausal women with prediabetes. While this was not a cardiovascular endpoint trial, the metabolic effects have direct cardiovascular relevance: insulin resistance is among the strongest independent risk factors for cardiovascular disease.

Liao et al. (2021) in the Journal of the International Society of Sports Nutrition tested 300 mg NMN/day for 6 weeks in 48 amateur runners and found improvements in aerobic capacity and oxygen utilization. These performance markers have mechanistic connections to cardiovascular function through mitochondrial efficiency in cardiac and vascular smooth muscle cells.

The evidence base for NMN's cardiovascular effects is currently more robust in animal models than in humans. That doesn't make the data irrelevant—but it means claims should be stated carefully. If you want a detailed picture of NMN benefits with actual human evidence, cardiovascular outcomes are squarely in the "promising preclinical, emerging human" category.

The Mechanism: How NAD+ Protects Vascular Function

The cardiovascular system depends on NAD+ through several distinct molecular pathways that explain why declining NAD+ accelerates vascular aging:

SIRT1 and endothelial nitric oxide. SIRT1 is a NAD+-dependent deacetylase that directly regulates endothelial nitric oxide synthase (eNOS). When NAD+ is adequate, SIRT1 keeps eNOS active by deacetylating it at Lys1176, a modification required for full enzymatic activity. Nitric oxide produced by eNOS is the primary vasodilatory signal in blood vessels—it relaxes vascular smooth muscle, reduces platelet aggregation, and suppresses inflammatory gene expression in the endothelium. As NAD+ declines with age, SIRT1 activity falls, eNOS becomes less active, and nitric oxide availability decreases. This manifests clinically as reduced flow-mediated dilation, increased peripheral vascular resistance, and elevated blood pressure.

SIRT3 and cardiac mitochondrial efficiency. Cardiac muscle cells operate continuously and have exceptionally high mitochondrial density and ATP demand. SIRT3, a mitochondria-localized sirtuin, deacetylates and activates multiple complexes of the electron transport chain, including Complex I (NADH dehydrogenase). NAD+ depletion reduces SIRT3 activity, impairing ATP synthesis in cardiomyocytes—a mechanism implicated in age-related cardiomyopathy and diastolic dysfunction. Gomes et al. (2013) demonstrated in Cell that declining NAD+ disrupts nuclear-mitochondrial communication in a way that accelerates this process, and that restoring NAD+ through NMN partially reversed the phenotype in old mice.

CD38 and the inflammation-NAD+ depletion loop. CD38, an NAD+-consuming ectoenzyme, increases dramatically with age and chronic inflammation—both of which are central to cardiovascular disease pathophysiology. CD38 upregulation creates a positive feedback loop where inflammation depletes NAD+, which reduces sirtuin activity, which worsens inflammatory NF-κB signaling. In atherosclerosis, macrophage foam cells in arterial plaques have significantly elevated CD38 activity. This means cardiovascular disease progression may actually accelerate NAD+ depletion in the very tissues where NAD+ protection matters most.

PARP activation and vascular DNA repair. Oxidative stress—a central feature of hypertension, diabetes, and atherosclerosis—triggers PARP enzymes that consume large amounts of NAD+ while repairing damaged DNA in vascular cells. When chronic oxidative stress outpaces repair capacity, this can deplete NAD+ faster than it can be replenished through the salvage pathway, accelerating endothelial dysfunction and smooth muscle cell phenotype switching from contractile to pro-inflammatory forms.

For those tracking the broader picture of how NAD+ declines with age, the cardiovascular system is particularly vulnerable because it cannot rely on intermittent periods of reduced demand—the heart beats continuously from before birth.

Effects on Blood Pressure

The relationship between NAD+ and blood pressure operates primarily through the eNOS-nitric oxide pathway described above. When SIRT1 activity declines due to reduced NAD+, nitric oxide availability decreases and blood vessels lose capacity for appropriate vasodilation. The result is increased peripheral vascular resistance—one of the fundamental hemodynamic drivers of essential hypertension.

In animal models, NMN supplementation consistently improves blood pressure in hypertensive and aged models. The de Picciotto et al. (2016) study specifically measured carotid pulse wave velocity as a marker of arterial stiffness and found significant reductions in aged NMN-treated mice. Since arterial stiffness is a major determinant of systolic blood pressure in older adults, these findings have direct hemodynamic implications.

Human data on NMN and blood pressure specifically remains limited. One unpublished pilot study (n=21, 300 mg/day, 12 weeks) presented at an aging conference reported modest systolic blood pressure reduction, but this has not been peer-reviewed. The most relevant published human data remains the metabolic improvements in Yoshino 2021, which included improvements in insulin-stimulated muscle glucose uptake—a metric with known hemodynamic implications since hyperinsulinemia contributes to sympathetic nervous system activation and blood pressure elevation.

Until larger, dedicated cardiovascular trials report, blood pressure reduction cannot be listed as an established clinical effect of NMN supplementation. The mechanistic rationale is compelling, but compelling mechanisms have misled medicine before.

Endothelial Function and Arterial Stiffness

Endothelial function—typically measured by flow-mediated dilation (FMD) of the brachial artery—is one of the most validated non-invasive biomarkers of cardiovascular risk. A 1% reduction in FMD corresponds to approximately 8–13% increased risk of cardiovascular events in prospective epidemiological studies. The NAD+-SIRT1-eNOS pathway directly determines endothelial responsiveness to shear stress—the primary physiological stimulus for nitric oxide release—making FMD a logical endpoint for NMN trials.

Arterial stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), is another validated cardiovascular risk marker that increases with age. Stiffening occurs through several mechanisms: collagen cross-linking in the arterial wall, loss of vascular smooth muscle elasticity, and reduced elastin content. NAD+-SIRT1 signaling in vascular smooth muscle cells influences extracellular matrix remodeling through effects on matrix metalloproteinases, providing a mechanistic connection between NAD+ status and arterial wall mechanics.

No published human RCT has yet reported FMD or cfPWV as primary endpoints for NMN supplementation, though ongoing trials at the University of Colorado (David Seals laboratory) include these measurements. These will be critical for translating the preclinical findings to human clinical relevance.

NMN and Cardiac Muscle Function

Beyond vascular effects, NMN's impact on cardiac mitochondrial function deserves separate attention. The heart is the most metabolically demanding tissue in the body, producing and consuming approximately 6 kg of ATP daily. This demand is met almost entirely by oxidative phosphorylation—a process directly dependent on NAD+ availability for NADH production in the TCA cycle and NAD+ regeneration in the electron transport chain.

Age-related diastolic dysfunction—the most common form of heart failure in older adults—is characterized by impaired cardiac relaxation due to reduced mitochondrial efficiency in cardiomyocytes. SIRT3's role in maintaining mitochondrial protein acetylation balance is critical here: when NAD+ declines and SIRT3 activity falls, mitochondrial protein hyperacetylation impairs ATP synthase activity and calcium cycling in cardiomyocytes, both of which contribute to diastolic dysfunction phenotypes.

Preclinical models have shown NMN supplementation preserved cardiac function in aged mice, including systolic function, diastolic function, and mitochondrial respiration in isolated cardiomyocytes. These findings are mechanistically coherent but have not yet been replicated in humans. The connection to the broader NMN and neurological health literature is relevant here: the brain and heart share a dependence on high mitochondrial efficiency that makes both particularly vulnerable to NAD+ decline.

Who Benefits Most

Based on current evidence, the cardiovascular rationale for NMN supplementation is strongest in specific populations:

Adults over 50 with metabolic risk factors. The populations in published NMN trials showing the clearest metabolic benefits are postmenopausal women with prediabetes and middle-aged athletes—groups where the intersection of reduced NAD+ and elevated cardiovascular risk is most direct. The Yoshino 2021 insulin sensitivity findings in postmenopausal prediabetic women are particularly relevant given that insulin resistance is a major cardiovascular risk multiplier.

Individuals with chronically elevated inflammatory markers. Given CD38's role in inflammation-driven NAD+ depletion, people with elevated CRP, IL-6, or other inflammatory markers may have greater NAD+ deficits and potentially more to gain from supplementation. This remains hypothesis-generating rather than clinically established.

Those with documented arterial stiffness or early endothelial dysfunction. If a patient has documented vascular changes on non-invasive testing, the mechanistic case for NAD+ repletion supporting vascular function is strongest. This is the population most likely to be enrolled in ongoing human trials.

The evidence is weakest for young, healthy adults with no cardiovascular risk factors. Raising already-adequate NAD+ levels in this group is not established to provide incremental cardiovascular benefit.

Practical Takeaways

• NAD+ decline is mechanistically linked to endothelial dysfunction, arterial stiffness, and cardiac mitochondrial decline — but human cardiovascular endpoint trials for NMN are still ongoing and unpublished.
• The strongest current human evidence for cardiovascular-relevant benefits is the Yoshino 2021 insulin sensitivity data in prediabetic women — a population with direct cardiovascular risk.
• Preclinical evidence is robust and mechanistically coherent across multiple pathways (SIRT1-eNOS, SIRT3-mitochondria, CD38-inflammation, PARP-DNA repair).
• Bio:sudo NMN 1000mg provides 1,000 mg per serving with third-party purity testing; for cardiovascular-relevant effects, doses of 250–500 mg are closer to the published human literature.
• NMN should be considered an adjunct to — not a replacement for — lifestyle interventions with established cardiovascular evidence: exercise, dietary improvement, smoking cessation, and blood pressure management.
• Watch for publications from the University of Colorado and Keio University vascular aging trials, expected 2026–2027, which will provide the first rigorous human FMD and arterial stiffness data for NMN.

Bottom Line

The mechanistic case for NMN's cardiovascular effects is one of the strongest in the NAD+ supplement literature — NAD+ directly regulates the enzymes governing endothelial function, mitochondrial efficiency in cardiac cells, and DNA repair in vascular tissue, and multiple well-designed preclinical studies confirm these pathways operate as predicted. However, human cardiovascular endpoint trials are not yet complete, and honest assessment requires acknowledging that cardiovascular benefit in humans is mechanistically plausible and biologically coherent, but not yet clinically established. The existing human evidence — metabolic improvements in high-risk populations — has real cardiovascular relevance, and that remains the honest current summary.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners." J Int Soc Sports Nutr. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---